ID   KCNN4_HUMAN             Reviewed;         427 AA.
AC   O15554; Q53XR4;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   07-APR-2021, entry version 183.
DE   RecName: Full=Intermediate conductance calcium-activated potassium channel protein 4;
DE            Short=SK4;
DE            Short=SKCa 4;
DE            Short=SKCa4;
DE   AltName: Full=IKCa1;
DE            Short=IK1;
DE   AltName: Full=KCa3.1;
DE   AltName: Full=KCa4;
DE   AltName: Full=Putative Gardos channel;
GN   Name=KCNN4; Synonyms=IK1, IKCA1, KCA4, SK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=9380751; DOI=10.1073/pnas.94.20.11013;
RA   Joiner W.J., Wang L.-Y., Tang M.D., Kaczmarek L.K.;
RT   "hSK4, a member of a novel subfamily of calcium-activated potassium
RT   channels.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:11013-11018(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=9326665; DOI=10.1073/pnas.94.21.11651;
RA   Ishii T.M., Silvia C., Hirschberg B., Bond C.T., Adelman J.P., Maylie J.;
RT   "A human intermediate conductance calcium-activated potassium channel.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:11651-11656(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lymph node;
RX   PubMed=9407042; DOI=10.1074/jbc.272.52.32723;
RA   Logsdon N.J., Kang J., Togo J.A., Christian E.P., Aiyar J.;
RT   "A novel gene, hKCa4, encodes the calcium-activated potassium channel in
RT   human T lymphocytes.";
RL   J. Biol. Chem. 272:32723-32726(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9693050; DOI=10.1006/geno.1998.5333;
RA   Ghanshani S., Coleman M., Gustavsson P., Wu A.C., Gargus J.J., Gutman G.A.,
RA   Dahl N., Mohrenweiser H., Chandy K.G.;
RT   "Human calcium-activated potassium channel gene KCNN4 maps to chromosome
RT   19q13.2 in the region deleted in diamond-blackfan anemia.";
RL   Genomics 51:160-161(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10961988; DOI=10.1074/jbc.m003941200;
RA   Ghanshani S., Wulff H., Miller M.J., Rohm H., Neben A., Gutman G.A.,
RA   Cahalan M.D., Chandy K.G.;
RT   "Up-regulation of the IKCa1 potassium channel during T-cell activation.
RT   Molecular mechanism and functional consequences.";
RL   J. Biol. Chem. 275:37137-37149(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Myometrium;
RA   Mazzone J.N., Kaiser R.A., Buxton I.L.O.;
RT   "Characterization of calcium-activated potassium channels in human
RT   myometrium.";
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 227-367.
RA   Golding S., Culliford S.J., Ellory J.C.;
RT   "hIK1 (putative Gardos channel) PCR product amplified from the K562 human
RT   erythroleukemic cell line.";
RL   Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   INTERACTION WITH CALMODULIN.
RX   PubMed=10026195; DOI=10.1074/jbc.274.9.5746;
RA   Fanger C.M., Ghanshani S., Logsdon N.J., Rauer H., Kalman K., Zhou J.,
RA   Beckingham K., Chandy K.G., Cahalan M.D., Aiyar J.;
RT   "Calmodulin mediates calcium-dependent activation of the intermediate
RT   conductance KCa channel, IKCa1.";
RL   J. Biol. Chem. 274:5746-5754(1999).
RN   [12]
RP   MUTAGENESIS OF THR-250 AND VAL-275.
RX   PubMed=11425865; DOI=10.1074/jbc.m105231200;
RA   Wulff H., Gutman G.A., Cahalan M.D., Chandy K.G.;
RT   "Delineation of the clotrimazole/TRAM-34 binding site on the intermediate
RT   conductance calcium-activated potassium channel, IKCa1.";
RL   J. Biol. Chem. 276:32040-32045(2001).
RN   [13]
RP   INTERACTION WITH MTMR6.
RX   PubMed=15831468; DOI=10.1128/mcb.25.9.3630-3638.2005;
RA   Srivastava S., Li Z., Lin L., Liu G., Ko K., Coetzee W.A., Skolnik E.Y.;
RT   "The phosphatidylinositol 3-phosphate phosphatase myotubularin-related
RT   protein 6 (MTMR6) is a negative regulator of the Ca2+-activated K+ channel
RT   KCa3.1.";
RL   Mol. Cell. Biol. 25:3630-3638(2005).
RN   [14]
RP   FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT HIS-358.
RX   PubMed=17157250; DOI=10.1016/j.molcel.2006.11.012;
RA   Srivastava S., Li Z., Ko K., Choudhury P., Albaqumi M., Johnson A.K.,
RA   Yan Y., Backer J.M., Unutmaz D., Coetzee W.A., Skolnik E.Y.;
RT   "Histidine phosphorylation of the potassium channel KCa3.1 by nucleoside
RT   diphosphate kinase B is required for activation of KCa3.1 and CD4 T
RT   cells.";
RL   Mol. Cell 24:665-675(2006).
RN   [15]
RP   FUNCTION, ACTIVITY REGULATION, AND DEPHOSPHORYLATION BY PTHP1.
RX   PubMed=18796614; DOI=10.1073/pnas.0803678105;
RA   Srivastava S., Zhdanova O., Di L., Li Z., Albaqumi M., Wulff H.,
RA   Skolnik E.Y.;
RT   "Protein histidine phosphatase 1 negatively regulates CD4 T cells by
RT   inhibiting the K+ channel KCa3.1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:14442-14446(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [17]
RP   FUNCTION.
RX   PubMed=24591580; DOI=10.1073/pnas.1311029111;
RA   Maekawa M., Terasaka S., Mochizuki Y., Kawai K., Ikeda Y., Araki N.,
RA   Skolnik E.Y., Taguchi T., Arai H.;
RT   "Sequential breakdown of 3-phosphorylated phosphoinositides is essential
RT   for the completion of macropinocytosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:E978-E987(2014).
RN   [18]
RP   VARIANTS DHS2 MET-282 AND HIS-352.
RX   PubMed=26178367; DOI=10.1002/ajh.24117;
RA   Andolfo I., Russo R., Manna F., Shmukler B.E., Gambale A., Vitiello G.,
RA   De Rosa G., Brugnara C., Alper S.L., Snyder L.M., Iolascon A.;
RT   "Novel Gardos channel mutations linked to dehydrated hereditary
RT   stomatocytosis (xerocytosis).";
RL   Am. J. Hematol. 90:921-926(2015).
RN   [19]
RP   INVOLVEMENT IN DHS2, VARIANT DHS2 HIS-352, SUBCELLULAR LOCATION, AND
RP   FUNCTION.
RX   PubMed=26148990; DOI=10.1182/blood-2015-04-642496;
RA   Rapetti-Mauss R., Lacoste C., Picard V., Guitton C., Lombard E.,
RA   Loosveld M., Nivaggioni V., Dasilva N., Salgado D., Desvignes J.P.,
RA   Beroud C., Viout P., Bernard M., Soriani O., Vinti H., Lacroze V.,
RA   Feneant-Thibault M., Thuret I., Guizouarn H., Badens C.;
RT   "A mutation in the Gardos channel is associated with hereditary
RT   xerocytosis.";
RL   Blood 126:1273-1280(2015).
RN   [20]
RP   VARIANTS DHS2 GLU-282 AND MET-282.
RX   PubMed=26198474; DOI=10.1182/blood-2015-07-657957;
RA   Glogowska E., Lezon-Geyda K., Maksimova Y., Schulz V.P., Gallagher P.G.;
RT   "Mutations in the Gardos channel (KCNN4) are associated with hereditary
RT   xerocytosis.";
RL   Blood 126:1281-1284(2015).
CC   -!- FUNCTION: Forms a voltage-independent potassium channel that is
CC       activated by intracellular calcium (PubMed:26148990). Activation is
CC       followed by membrane hyperpolarization which promotes calcium influx.
CC       Required for maximal calcium influx and proliferation during the
CC       reactivation of naive T-cells (PubMed:17157250, PubMed:18796614). Plays
CC       a role in the late stages of EGF-induced macropinocytosis
CC       (PubMed:24591580). {ECO:0000269|PubMed:17157250,
CC       ECO:0000269|PubMed:18796614, ECO:0000269|PubMed:24591580,
CC       ECO:0000269|PubMed:26148990}.
CC   -!- ACTIVITY REGULATION: The channel is inhibited by clotrimazole and
CC       charybdotoxin but is insensitive to apamin.
CC       {ECO:0000269|PubMed:17157250, ECO:0000269|PubMed:18796614}.
CC   -!- SUBUNIT: Heterotetramer of potassium channel proteins (Probable).
CC       Interacts with MTMR6. {ECO:0000269|PubMed:10026195,
CC       ECO:0000269|PubMed:15831468, ECO:0000305}.
CC   -!- INTERACTION:
CC       O15554; Q13323: BIK; NbExp=3; IntAct=EBI-2924473, EBI-700794;
CC       O15554; P0DP25: CALM3; NbExp=2; IntAct=EBI-2924473, EBI-397435;
CC       O15554; P13569: CFTR; NbExp=5; IntAct=EBI-2924473, EBI-349854;
CC       O15554; Q8TBE1: CNIH3; NbExp=3; IntAct=EBI-2924473, EBI-12208021;
CC       O15554; Q14802-3: FXYD3; NbExp=3; IntAct=EBI-2924473, EBI-12175685;
CC       O15554; Q8TDT2: GPR152; NbExp=3; IntAct=EBI-2924473, EBI-13345167;
CC       O15554; Q9NRX4: PHPT1; NbExp=2; IntAct=EBI-2924473, EBI-740955;
CC       O15554; Q01453: PMP22; NbExp=3; IntAct=EBI-2924473, EBI-2845982;
CC       O15554; Q9BRI3: SLC30A2; NbExp=3; IntAct=EBI-2924473, EBI-8644112;
CC       O15554; P61266: STX1B; NbExp=3; IntAct=EBI-2924473, EBI-9071709;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26148990};
CC       Multi-pass membrane protein {ECO:0000255}.
CC   -!- TISSUE SPECIFICITY: Widely expressed in non-excitable tissues.
CC   -!- INDUCTION: Up-regulated by phorbol myristate acetate (PMA) and
CC       phytohemagglutinin (PHA) in T-cells.
CC   -!- PTM: Phosphorylation at His-358 by NDKB activates the channel, and
CC       conversely it's dephosphorylation by PHPT1 inhibits the channel.
CC       {ECO:0000269|PubMed:17157250}.
CC   -!- DISEASE: Dehydrated hereditary stomatocytosis 2 (DHS2) [MIM:616689]: An
CC       autosomal dominant hemolytic anemia characterized by primary
CC       erythrocyte dehydration. Erythrocytes exhibit decreased total cation
CC       and potassium content that are not accompanied by a proportional net
CC       gain of sodium and water. Affected individuals typically manifest mild
CC       to moderate compensated hemolytic anemia, with an increased erythrocyte
CC       mean corpuscular hemoglobin concentration and a decreased osmotic
CC       fragility, both of which reflect cellular dehydration. Their red cells
CC       exhibit a panel of various shape abnormalities such as elliptocytes,
CC       hemighosts, schizocytes, and very rare stomatocytic cells.
CC       Complications such as splenomegaly and cholelithiasis, resulting from
CC       increased red cell trapping in the spleen and elevated bilirubin
CC       levels, respectively, may occur. {ECO:0000269|PubMed:26148990,
CC       ECO:0000269|PubMed:26178367, ECO:0000269|PubMed:26198474}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the potassium channel KCNN family. KCa3.1/KCNN4
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF000972; AAB82739.1; -; mRNA.
DR   EMBL; AF022150; AAC23541.1; -; mRNA.
DR   EMBL; AF022797; AAC51913.1; -; mRNA.
DR   EMBL; AF033021; AAC36804.1; -; mRNA.
DR   EMBL; AF305735; AAG26917.1; -; Genomic_DNA.
DR   EMBL; AF305731; AAG26917.1; JOINED; Genomic_DNA.
DR   EMBL; AF305732; AAG26917.1; JOINED; Genomic_DNA.
DR   EMBL; AF305733; AAG26917.1; JOINED; Genomic_DNA.
DR   EMBL; AF305734; AAG26917.1; JOINED; Genomic_DNA.
DR   EMBL; AF395661; AAK81862.1; -; mRNA.
DR   EMBL; BT007426; AAP36094.1; -; mRNA.
DR   EMBL; CH471126; EAW57230.1; -; Genomic_DNA.
DR   EMBL; BC015337; AAH15337.1; -; mRNA.
DR   EMBL; AF053403; AAC35281.1; -; mRNA.
DR   CCDS; CCDS12630.1; -.
DR   RefSeq; NP_002241.1; NM_002250.2.
DR   PDB; 6CNM; EM; 3.40 A; A/B/C/D=1-427.
DR   PDB; 6CNN; EM; 3.50 A; A/B/C/D=1-427.
DR   PDB; 6CNO; EM; 4.70 A; A/B/C/D=1-427.
DR   PDB; 6D42; X-ray; 1.75 A; A/B=376-415.
DR   PDBsum; 6CNM; -.
DR   PDBsum; 6CNN; -.
DR   PDBsum; 6CNO; -.
DR   PDBsum; 6D42; -.
DR   SMR; O15554; -.
DR   BioGRID; 109984; 22.
DR   DIP; DIP-48598N; -.
DR   IntAct; O15554; 13.
DR   STRING; 9606.ENSP00000262888; -.
DR   BindingDB; O15554; -.
DR   ChEMBL; CHEMBL4305; -.
DR   DrugBank; DB00257; Clotrimazole.
DR   DrugBank; DB01159; Halothane.
DR   DrugBank; DB01110; Miconazole.
DR   DrugBank; DB00721; Procaine.
DR   DrugBank; DB00468; Quinine.
DR   DrugBank; DB09089; Trimebutine.
DR   DrugCentral; O15554; -.
DR   GuidetoPHARMACOLOGY; 384; -.
DR   TCDB; 1.A.1.16.2; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; O15554; -.
DR   PhosphoSitePlus; O15554; -.
DR   SwissPalm; O15554; -.
DR   BioMuta; KCNN4; -.
DR   EPD; O15554; -.
DR   jPOST; O15554; -.
DR   MassIVE; O15554; -.
DR   MaxQB; O15554; -.
DR   PaxDb; O15554; -.
DR   PeptideAtlas; O15554; -.
DR   PRIDE; O15554; -.
DR   ProteomicsDB; 48757; -.
DR   Antibodypedia; 31124; 295 antibodies.
DR   DNASU; 3783; -.
DR   Ensembl; ENST00000648319; ENSP00000496939; ENSG00000104783.
DR   GeneID; 3783; -.
DR   KEGG; hsa:3783; -.
DR   UCSC; uc002oxl.3; human.
DR   CTD; 3783; -.
DR   DisGeNET; 3783; -.
DR   GeneCards; KCNN4; -.
DR   HGNC; HGNC:6293; KCNN4.
DR   HPA; ENSG00000104783; Tissue enhanced (placenta, salivary gland).
DR   MalaCards; KCNN4; -.
DR   MIM; 602754; gene.
DR   MIM; 616689; phenotype.
DR   neXtProt; NX_O15554; -.
DR   OpenTargets; ENSG00000104783; -.
DR   Orphanet; 3202; Dehydrated hereditary stomatocytosis.
DR   PharmGKB; PA222; -.
DR   VEuPathDB; HostDB:ENSG00000104783.11; -.
DR   eggNOG; KOG3684; Eukaryota.
DR   GeneTree; ENSGT00950000182904; -.
DR   HOGENOM; CLU_014617_5_2_1; -.
DR   InParanoid; O15554; -.
DR   OMA; CVIHPVG; -.
DR   OrthoDB; 907751at2759; -.
DR   PhylomeDB; O15554; -.
DR   TreeFam; TF315015; -.
DR   PathwayCommons; O15554; -.
DR   Reactome; R-HSA-1296052; Ca2+ activated K+ channels.
DR   SIGNOR; O15554; -.
DR   BioGRID-ORCS; 3783; 5 hits in 993 CRISPR screens.
DR   ChiTaRS; KCNN4; human.
DR   GeneWiki; KCNN4; -.
DR   GenomeRNAi; 3783; -.
DR   Pharos; O15554; Tchem.
DR   PRO; PR:O15554; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; O15554; protein.
DR   Bgee; ENSG00000104783; Expressed in saliva-secreting gland and 168 other tissues.
DR   ExpressionAtlas; O15554; baseline and differential.
DR   Genevisible; O15554; HS.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0043025; C:neuronal cell body; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031982; C:vesicle; IDA:BHF-UCL.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; TAS:ProtInc.
DR   GO; GO:0015269; F:calcium-activated potassium channel activity; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IBA:GO_Central.
DR   GO; GO:0022894; F:Intermediate conductance calcium-activated potassium channel activity; IBA:GO_Central.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:BHF-UCL.
DR   GO; GO:0016286; F:small conductance calcium-activated potassium channel activity; IEA:InterPro.
DR   GO; GO:0006816; P:calcium ion transport; IDA:BHF-UCL.
DR   GO; GO:0006884; P:cell volume homeostasis; IEA:Ensembl.
DR   GO; GO:0006952; P:defense response; TAS:ProtInc.
DR   GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW.
DR   GO; GO:0006811; P:ion transport; IBA:GO_Central.
DR   GO; GO:0045332; P:phospholipid translocation; IEA:Ensembl.
DR   GO; GO:1901381; P:positive regulation of potassium ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IEA:Ensembl.
DR   GO; GO:0050862; P:positive regulation of T cell receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0071805; P:potassium ion transmembrane transport; IBA:GO_Central.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   GO; GO:0046541; P:saliva secretion; IEA:Ensembl.
DR   GO; GO:0030322; P:stabilization of membrane potential; IDA:BHF-UCL.
DR   InterPro; IPR004178; CaM-bd_dom.
DR   InterPro; IPR036122; CaM-bd_dom_sf.
DR   InterPro; IPR015449; K_chnl_Ca-activ_SK.
DR   InterPro; IPR013099; K_chnl_dom.
DR   PANTHER; PTHR10153; PTHR10153; 1.
DR   Pfam; PF02888; CaMBD; 1.
DR   Pfam; PF07885; Ion_trans_2; 1.
DR   Pfam; PF03530; SK_channel; 1.
DR   SMART; SM01053; CaMBD; 1.
DR   SUPFAM; SSF81327; SSF81327; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calmodulin-binding; Cell membrane; Disease variant;
KW   Hereditary hemolytic anemia; Immunity; Ion channel; Ion transport;
KW   Membrane; Phosphoprotein; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..427
FT                   /note="Intermediate conductance calcium-activated potassium
FT                   channel protein 4"
FT                   /id="PRO_0000155017"
FT   TRANSMEM        29..49
FT                   /note="Helical; Name=Segment S1"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        59..79
FT                   /note="Helical; Name=Segment S2"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        108..128
FT                   /note="Helical; Name=Segment S3"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        143..163
FT                   /note="Helical; Name=Segment S4"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        207..227
FT                   /note="Helical; Name=Segment S5"
FT                   /evidence="ECO:0000255"
FT   INTRAMEM        241..261
FT                   /note="Pore-forming; Name=Segment H5"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        265..285
FT                   /note="Helical; Name=Segment S6"
FT                   /evidence="ECO:0000255"
FT   REGION          286..347
FT                   /note="Calmodulin-binding"
FT   MOD_RES         358
FT                   /note="Phosphohistidine"
FT                   /evidence="ECO:0000269|PubMed:17157250"
FT   VARIANT         282
FT                   /note="V -> E (in DHS2; dbSNP:rs1057519077)"
FT                   /evidence="ECO:0000269|PubMed:26198474"
FT                   /id="VAR_074485"
FT   VARIANT         282
FT                   /note="V -> M (in DHS2; dbSNP:rs1057519076)"
FT                   /evidence="ECO:0000269|PubMed:26178367,
FT                   ECO:0000269|PubMed:26198474"
FT                   /id="VAR_074486"
FT   VARIANT         352
FT                   /note="R -> H (in DHS2; no effect on plasma membrane
FT                   localization; increases calcium-activated potassium channel
FT                   activity; dbSNP:rs774455945)"
FT                   /evidence="ECO:0000269|PubMed:26148990,
FT                   ECO:0000269|PubMed:26178367"
FT                   /id="VAR_074487"
FT   MUTAGEN         250
FT                   /note="T->S: Loss of sensitivity to triarylmethanes."
FT                   /evidence="ECO:0000269|PubMed:11425865"
FT   MUTAGEN         275
FT                   /note="V->A: Loss of sensitivity to triarylmethanes."
FT                   /evidence="ECO:0000269|PubMed:11425865"
FT   CONFLICT        66
FT                   /note="S -> G (in Ref. 6; AAK81862)"
FT                   /evidence="ECO:0000305"
FT   HELIX           12..50
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   TURN            51..56
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           57..91
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           96..99
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           104..114
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           149..154
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           155..161
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           162..170
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   TURN            172..174
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           177..186
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           192..202
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           204..226
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   TURN            230..233
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           237..248
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   STRAND          254..256
FT                   /evidence="ECO:0007744|PDB:6CNN"
FT   HELIX           261..287
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           293..330
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   TURN            335..337
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           338..368
FT                   /evidence="ECO:0007744|PDB:6CNM"
FT   HELIX           378..413
FT                   /evidence="ECO:0007744|PDB:6D42"
SQ   SEQUENCE   427 AA;  47696 MW;  23F9AF66609B410F CRC64;
     MGGDLVLGLG ALRRRKRLLE QEKSLAGWAL VLAGTGIGLM VLHAEMLWFG GCSWALYLFL
     VKCTISISTF LLLCLIVAFH AKEVQLFMTD NGLRDWRVAL TGRQAAQIVL ELVVCGLHPA
     PVRGPPCVQD LGAPLTSPQP WPGFLGQGEA LLSLAMLLRL YLVPRAVLLR SGVLLNASYR
     SIGALNQVRF RHWFVAKLYM NTHPGRLLLG LTLGLWLTTA WVLSVAERQA VNATGHLSDT
     LWLIPITFLT IGYGDVVPGT MWGKIVCLCT GVMGVCCTAL LVAVVARKLE FNKAEKHVHN
     FMMDIQYTKE MKESAARVLQ EAWMFYKHTR RKESHAARRH QRKLLAAINA FRQVRLKHRK
     LREQVNSMVD ISKMHMILYD LQQNLSSSHR ALEKQIDTLA GKLDALTELL STALGPRQLP
     EPSQQSK
//
